New hope for myelofibrosis patients who failed standard therapy?

This study tested a drug called selinexor in 17 people with a rare bone marrow cancer (myelofibrosis) that did not respond to or could not tolerate standard JAK inhibitor treatments. The main goal was to see if the drug could shrink an enlarged spleen by at least 35%. The trial was stopped early, so results are limited, but it aimed to find a new option for patients with few alternatives.